Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

Cited by (1,019)

Items 901–1,000 of 1,019

1. Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes.
   Francesco Paneni, Sarah Costantino, Francesco Cosentino · 2014 · PubMed
2. Oral retinoids and plasma lipids
   Jessica Sparks Lilley, MacRae F. Linton, Sergio Fazio · 2013 · Dermatologic Therapy
3. Drug and Gene Delivery using Sonoporation for Cardiovascular Disease.
   Jason Castle, S. Feinstein · 2016 · Advances in Experimental Medicine and Biology
4. HDL—is it too big to fail?
   Dominic S. Ng, Norman C.W. Wong, Robert Alexander Hegele · 2013 · Nature Reviews Endocrinology
5. Cholesterol, Lipoproteins, High-sensitivity C-reactive Protein, and Other Risk Factors for Atherosclerosis
   Joseph William Rudolf, Kent B Lewandrowski · 2014 · Clinics in Laboratory Medicine
6. Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy
   Matthew K. Ito · 2012 · Annals of Pharmacotherapy
7. Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol
   Manabu Ogita, Katsumi Miyauchi, Tadashi Miyazaki, Ryo Naito, Hirokazu Konishi, Shuta Tsuboi, Tomotaka Dohi, Takatoshi Kasai, Takayuki Yokoyama, Shinya Okazaki et al. · 2013 · Heart and Vessels
8. High Density Lipoprotein: A Therapeutic Target in Type 2 Diabetes
   Philip J. Barter · 2013 · Endocrinology and Metabolism
9. Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
   Katrina L. Ellis, Amanda J. Hooper, John R. Burnett, Gerald Francis Watts · 2016 · Nature Reviews Endocrinology
10. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options
    Panagiotis G. Anagnostis, Spyridon Ν. Karras, Irene V. Lambrinoudaki, John C. Stevenson, Dimitrios G. Goulis · 2016 · International Journal of Clinical Practice
11. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey
    Joseph Salami, Haider Javed Warraich, Javier Valero Elizondo, Erica Sarah Spatz, Nihar R. Desai, Jamal S. Rana, Salim S. Virani, Ron Blankstein, Amit Khera, Michael Joseph Blaha et al. · 2018 · Journal of the American Heart Association
12. High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes
    William Sean Davidson, AMY SANGHAVI SHAH · 2019 · Methodist DeBakey Cardiovascular Journal
13. Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?
    Anne Langsted, Børge Grønne Nordestgaard · 2020 · Current Opinion in Lipidology
14. Lipoprotein (a): When to Measure and How to Treat?
    David Rhainds, Mathieu R. Brodeur, Jean‐Claude Tardif · 2021 · Current Atherosclerosis Reports
15. Free Cholesterol Bioavailability and Atherosclerosis
    Rei J. Abe, Jun‐ichi Abe, Minh Thi Nguyen, Elizabeth A. Olmsted‐Davis, Abrar Mamun, Priyanka Banerjee, John P. Cooke, Longhou Fang, Henry J. Pownall, Nhat-Tu Le · 2022 · Current Atherosclerosis Reports
16. Effects of HDL-modifiers on cardiovascular outcomes: A meta-analysis of randomized trials
    Monica Verdoia, Alon Schaffer, Harry Suryapranata, Giuseppe De Luca · 2014 · Nutrition Metabolism and Cardiovascular Diseases
17. Cholesterol Efflux Capacity
    Amit V. Khera, Daniel James Rader · 2013 · Arteriosclerosis Thrombosis and Vascular Biology
18. High-Density Lipoprotein Particle Number
    Emil M. deGoma, Daniel James Rader · 2012 · Journal of the American College of Cardiology
19. PCSK9 Inhibition
    Robert A. Vogel · 2012 · Journal of the American College of Cardiology
20. Association between niacin and mortality among patients with cancer in the NHANES retrospective cohort
    Hongan Ying, Lijie Gao, Nansheng Liao, Xijuan Xu, Wenfeng Yu, Weiwen Hong · 2022 · BMC Cancer
21. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
    Georgios Tsioulos, Dimitris C. Kounatidis, Natalia G. Vallianou, Aikaterini Poulaki, Evangelia Kotsi, Gerasimos Socrates Christodoulatos, Dimitrios Tsilingiris, Ιrene Karampela, Alexandros Skourtis, Μaria Dalamaga · 2024 · International Journal of Molecular Sciences
22. HDL and Atherothrombotic Vascular Disease
    Wijtske Annema, Arnold von Eckardstein, Petri T. Kovanen · 2014 · Handbook of experimental pharmacology
23. Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention
    Payal Kohli, Seamus Paul Whelton, Steven Hsu, Clyde W. Yancy, Neil J. Stone, Jonathan Chrispin, Nisha Aggarwal Gilotra, Brian Allan Houston, M. Dominique Ashen, Seth Shay Martin et al. · 2014 · Journal of the American Heart Association
24. Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence
    Melissa E. Stauffer, Lauren Weisenfluh, Alan Morrison · 2013 · Vascular Health and Risk Management
25. Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?
    Daniel B. Larach, Emil M. deGoma, Daniel James Rader · 2012 · Current Cardiology Reports
26. New cholesterol guidelines: Worth the wait?
    Chad E. Raymond, Leslie Cho, Michael B. Rocco, Stanley L. Hazen · 2014 · Cleveland Clinic Journal of Medicine
27. Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction
    Charles Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, John Hunter Alexander, Philippe Gabríel Steg, Abraham Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D’Andrea et al. · 2016 · American Heart Journal
28. Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation
    Clara Minto, Maria Gabriella Vecchio, Manfred Lamprecht, Darío Gregori · 2017 · Nutrition Reviews
29. Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men
    Leah E. Cahill, Frank M. Sacks, Eric B. Rimm, Majken K. Jensen · 2019 · Journal of Lipid Research
30. NAD+ Metabolism as an Emerging Therapeutic Target for Cardiovascular Diseases Associated With Sudden Cardiac Death
    Weiyi Xu, Le Li, Lilei Zhang · 2020 · Frontiers in Physiology
31. Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects
    Graziella E. Ronsein, Tomáš Vaisar, William Sean Davidson, Karin Bornfeldt, Jeffrey L. Probstfield, Kevin D. O’Brien, Xue-Qiao Zhao, Jay W. Heinecke · 2021 · Arteriosclerosis Thrombosis and Vascular Biology
32. Triglyceride levels and residual risk of atherosclerotic cardiovascular disease events and death in adults receiving statin therapy for primary or secondary prevention: insights from the KP REACH study
    Ambrosy, Andrew P., Yang, Jingrong, Sung, Sue Hee, Allen, Amanda R., Fitzpatrick, Jesse K., Rana, Jamal S., Wagner, Jeffrey, Philip, Sephy, Abrahamson, David, Granowitz, Craig et al. · 2021 · Journal of the American Heart Association
33. Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases
    Noemí Rotllán, Mercedes Camacho, Mireia Tondo, Elena M. G. Diarte‐Añazco, Marina Canyelles, Karen Alejandra Méndez‐Lara, Sònia Benı́tez, Núria Alonso, Dı́dac Mauricio, Joan Carles Escolá‐Gil et al. · 2021 · Antioxidants
34. A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs
    Venkata Mahesh Alla, Vrinda Agrawal, Andrew DeNazareth, Syed Mohiuddin, Sudha Ravilla, Marc Rendell · 2013 · Drugs
35. Lipoprotein a and cardiovascular disease current state and future directions for an enigmatic lipoprotein
    Salim S. Virani · 2017 · Frontiers in bioscience
36. CETP
    Jean‐Claude Tardif, David Rhainds, Éric Rhéaume, Marie‐Pierre Dubé · 2017 · Arteriosclerosis Thrombosis and Vascular Biology
37. HDL Hypothesis: Where Do We Stand Now?
    Tariq, Sayed M., Sidhu, Mandeep S., Toth, Peter P., Boden, William E. · 2014 · Current Atherosclerosis Reports
38. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
    Antonio Hernández Mijares, Juan Francisco Ascaso, Mariano Blasco, Ángel Brea, Ángel Díaz, Teresa Mantilla, Juan Pedro‐Botet, Xavier Pintó, Jesús Millán · 2019 · Clínica e Investigación en Arteriosclerosis (English Edition)
39. NAD + Precursors in Human Health and Disease: Current Status and Future Prospects
    Keisuke Yaku, Takashi Nakagawa · 2023 · Antioxidants and Redox Signaling
40. HDL-C: clinical equipoise and vascular endothelial function
    Steven Campbell, Jacques J. Genest · 2013 · Expert Review of Cardiovascular Therapy
41. Dislipemia aterogénica: prevalencia y control en las unidades de lípidos
    Juan Pedro‐Botet, Juana A. Flores‐Le Roux, José María Mostaza, Xavier Pintó, Juan J. de la Cruz, José R. Banegas · 2014 · Revista Clínica Española
42. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol
    Olga V. Savinova, Kristi Fillaus, William Stephen Harris, Gregory C. Shearer · 2015 · Atherosclerosis
43. Macrophage-Independent Regulation of Reverse Cholesterol Transport by Liver X Receptors
    Sarah R. Breevoort, Jerry J. Angdisen, Ira G. Schulman · 2014 · Arteriosclerosis Thrombosis and Vascular Biology
44. Beneficial Effects of Exercise-Based Cardiac Rehabilitation on High-Density Lipoprotein-Mediated Cholesterol Efflux Capacity in Patients with Acute Coronary Syndrome
    Shinji Koba, Makoto Ayaori, Harumi Uto‐Kondo, Fumiaki Furuyama, Yuya Yokota, Fumiyoshi Tsunoda, Makoto Shoji, Katsunori Ikewaki, Youichi Kobayashi · 2016 · Journal of Atherosclerosis and Thrombosis
45. Leveraging human genetics to guide drug target discovery
    Nathan O. Stitziel, Sekar Kathiresan · 2016 · Trends in Cardiovascular Medicine
46. Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease
    Denis P. Fouque, Marc G. Vervloet, Markus Ketteler · 2018 · Drugs
47. Lipid profile and long‐term outcome in premature myocardial infarction
    Max‐Paul Winter, Franz Wiesbauer, Hermann Blessberger, Noémi Pávó, Patrick Sulzgruber, Kurt Huber, Johann Wojta, Klaus Distelmaier, Irene Marthe Lang, Georg Goliasch · 2018 · European Journal of Clinical Investigation
48. Drug Therapy of Dyslipidemia in the Elderly
    Srikanth Yandrapalli, Shashvat Gupta, Gabriela Andries, Howard A. Cooper, Wilbert S. Aronow · 2019 · Drugs & Aging
49. High-Density Lipoprotein Function Is Reduced in Patients Affected by Genetic or Idiopathic Hypogonadism
    Maria Pia Adorni, Francesca Zimetti, Biagio Cangiano, Valeria Vezzoli, Franco Bernini, Donatella Caruso, Alberto Corsini, Cesare Riccardo Sirtori, Anna Maria Cariboni, Marco Bonomi et al. · 2019 · The Journal of Clinical Endocrinology & Metabolism
50. Association between plasma essential amino acids and atherogenic lipid profile in a Chinese population: A cross-sectional study
    Fenghua Wang, Jing Liu, Qiuju Deng, Yue Qi, Miao Wang, Ying Wang, Xingguang Zhang, Dong Hui Zhao · 2019 · Atherosclerosis
51. HDL Cholesterol as a Marker of Disease Severity and Prognosis in Patients with Pulmonary Arterial Hypertension
    Kamil Jonas, Grzegorz Kopeć · 2019 · International Journal of Molecular Sciences
52. Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review
    Peter Paul Toth, Prediman Krishan Shah, Norman E. Lepor · 2020 · American Journal of Preventive Cardiology
53. Cardiovascular effects of omega-3 fatty acids: Hope or hype?
    Sang‐Ho Jo, Seung Hwan Han, Sang‐Hyun Kim, Robert H. Eckel, Kwang Kon Koh · 2021 · Atherosclerosis
54. Causal Language in Observational Orthopaedic Research
    Nathan H. Varady, Aliya G. Feroe, Mark Alan Fontana, Antonia F. Chen · 2021 · Journal of Bone and Joint Surgery
55. Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies
    Ahmed Handhle, Adie Viljoen, Anthony S. Wierzbicki · 2021 · Vascular Health and Risk Management
56. Benefits of Streamlined Point-of-Care Trial Designs
    Robert M. Califf, Patrizia A. Cavazzoni, Janet Woodcock · 2022 · JAMA Internal Medicine
57. European guidelines for the treatment of dyslipidaemias: New concepts and future challenges
    Angela Pirillo, Manuela Casula, Alberico Luigi Catapano · 2023 · Pharmacological Research
58. HDL quality and functionality: what can proteins and genes predict?
    Eleni A. Karavia, Evangelia Zvintzou, Περιστέρα-Ιωάννα Πετροπούλου, Eva Xepapadaki, Caterina Constantinou, Kyriakos E. Kypreos · 2014 · Expert Review of Cardiovascular Therapy
59. Current and potential treatment options for hyperphosphatemia
    Fabio Carfagna, Lucia Del Vecchio, Giuseppe Pontoriero, Francesco Locatelli · 2018 · Expert Opinion on Drug Safety
60. Disorders of Lipid Metabolism
    Clay F. Semenkovich, Anne Carol Goldberg, Ira J. Goldberg · 2011 · Elsevier eBooks
61. Revisiting high-density lipoprotein cholesterol in cardiovascular disease: Is too much of a good thing always a good thing?
    Mohammad Al Zein, Alicia Khazzeka, Alessandro El Khoury, Jana Al Zein, Zoghaib Dima, Ali Hussein Eid · 2024 · Progress in Cardiovascular Diseases
62. The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)
    Gerd Brunner, Eric Y. Yang, Anirudh Kumar, Wensheng Sun, Salim S. Virani, Smita Negi, Tyler O. Murray, Peter H. Lin, Ron Cornelis Hoogeveen, Changyi Chen et al. · 2013 · Atherosclerosis
63. Strategies for vascular disease prevention: The role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a))
    Dhayana Dallmeier, Wolfgang Köenig · 2014 · Best Practice & Research Clinical Endocrinology & Metabolism
64. Dyslipidemia in Patients with Chronic and End-Stage Kidney Disease
    Jad Omran, Ashraf Al‐Dadah, Kevin C. Dellsperger · 2013 · Cardiorenal Medicine
65. Current guidelines for high-density lipoprotein cholesterol in therapy and future directions
    Erin D. Michos, Bishnu Hari Subedi, Parag H. Joshi, Steven Richard Jones, Seth Shay Martin, Michael Joseph Blaha · 2014 · Vascular Health and Risk Management
66. Scan-rescan reproducibility of quantitative assessment of inflammatory carotid atherosclerotic plaque using dynamic contrast-enhanced 3T CMR in a multi-center study
    Huijun Chen, Jie Sun, William S. Kerwin, Niranjan Balu, Moni Blazej Neradilek, Daniel S. Hippe, Daniel A. Isquith, Yunjing Xue, Kiyofumi Yamada, Suzanne Peck et al. · 2014 · Journal of Cardiovascular Magnetic Resonance
67. Diabetes and Dyslipidemia
    Kenneth R. Feingold, Carl Grünfeld · 2023 · Contemporary cardiology
68. Stable Ischemic Heart Disease
    Santosh Kumar Padala, Mandeep S. Sidhu, William E. Boden · 2016 · Springer eBooks
69. Plaque imaging to refine indications for emerging lipid-lowering drugs
    Mohammad Alkhalil, Joshua T. Chai, Robin P. Choudhury · 2016 · European Heart Journal - Cardiovascular Pharmacotherapy
70. Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease
    Frank van Buuren, Dieter Horstkotte, Cornelius Knabbe, Dennis Hinse, Klaus Peter Mellwig · 2017 · Clinical Research in Cardiology Supplements
71. Inclusion of Almonds in a Cholesterol-Lowering Diet Improves Plasma HDL Subspecies and Cholesterol Efflux to Serum in Normal-Weight Individuals with Elevated LDL Cholesterol
    Claire E. Berryman, Jennifer A Fleming, Penny M. Kris‐Etherton · 2017 · Journal of Nutrition
72. Obesity is associated with an altered HDL subspecies profile among adolescents with metabolic disease
    William Sean Davidson, Anna Heink, Hannah Sexmith, Lawrence M. Dolan, Scott M. Gordon, James D. Otvos, John Melchior, Deborah A. Elder, Jane C. Khoury, Esmond N. Geh et al. · 2017 · Journal of Lipid Research
73. Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk
    Kavisha Singh, Anand K. Rohatgi · 2018 · Journal of Thoracic Disease
74. Assessment of HDL Cholesterol Removal Capacity: Toward Clinical Application
    Ryuji Toh · 2018 · Journal of Atherosclerosis and Thrombosis
75. The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes
    Hanney Gonna, Kausik Kumar Ray · 2019 · Diabetes Obesity and Metabolism
76. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
    Richard Haynes, Elsa Valdés‐Márquez, Jemma C. Hopewell, Fang Chen, Jing Li, Sarah Parish, Martin Landray, Jane Armitage, Richard Haynes, Elsa Valdés‐Márquez et al. · 2019 · Clinical Therapeutics
77. Novel LCAT (Lecithin:Cholesterol Acyltransferase) Activator DS-8190a Prevents the Progression of Plaque Accumulation in Atherosclerosis Models
    Masato Sasaki, Mina Delawary, Hidetaka Sakurai, Hideki Kobayashi, Naoki Nakao, Hiromi Tsuru, Yumiko Fukushima, Shoko Honzumi, Sachiko Moriyama, Naoya Wada et al. · 2020 · Arteriosclerosis Thrombosis and Vascular Biology
78. Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
    Kiran Musunuru · 2020 · Annual Review of Medicine
79. Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly
    Tiziano LUCCHI · 2022 · Minerva Medica
80. Diabetic dyslipidaemia
    Subashini Chellappah Thambiah, Leslie C. Lai · 2021 · Practical Laboratory Medicine
81. Pharmacological interventions for heart failure in people with chronic kidney disease
    Meaghan Lunney, Marinella Ruospo, Patrizia Natale, Robert Ross Quinn, Paul Everett Ronksley, Ioannis Konstantinidis, Suetonia C. Palmer, Marcello A. Tonelli, Giovanni FM Strippoli, Pietro Ravani · 2020 · Cochrane Database of Systematic Reviews
82. Decoding microRNA drivers in atherosclerosis
    Tanwi Vartak, Soundharya Kumaresan, Eoin Patrick Brennan · 2022 · Bioscience Reports
83. Familial combined hyperlipidemia
    Marleen M. J. van Greevenbroek, Anton F. H. Stalenhoef, Jacqueline d Graaf, Martijn C.G.J. Brouwers · 2014 · Current Opinion in Lipidology
84. Extended‐release niacin increases anti‐apolipoprotein A‐I antibodies that block the antioxidant effect of high‐density lipoprotein–cholesterol: the EXPLORE clinical trial
    Joana R. Batuca, Marta Amaral, Catarina Favas, Filipe Seguro Paula, Paul R. J. Ames, Ana Luísa Papoila, José Delgado Alves · 2016 · British Journal of Clinical Pharmacology
85. Causal Effect of Lipids and Lipoproteins on Atherosclerosis
    Ference, Brian A. · 2018 · Cardiology Clinics
86. Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention
    Jeffrey E. Jones, Kevin S. Tang, Ailin Barseghian, Nathan D. Wong · 2023 · Journal of Clinical Medicine
87. Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations
    Gerald Francis Watts, Amanda Juniper, Frank van Bockxmeer, Zanfina Ademi, Danny Liew, Peter C. O'Leary · 2012 · International Journal of Evidence-Based Healthcare
88. Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients
    Rahul Yadav, Yifen Liu, See Kwok, Salam Hama, Michael W. France, Ruth Eatough, P. Pemberton, Jonathan D. Schofield, Tarza Jamal Siahmansur, Rayaz Ahmed Malik et al. · 2015 · Journal of the American Heart Association
89. Pharmacological management of diabetic dyslipidemia
    Theodosios D. Filippatos, Matilda Florentin, Marina Georgoula, Moses Elisaf · 2016 · Expert Review of Clinical Pharmacology
90. Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism
    Fatima Iqbal, Wendy S. Baker, Madiha Iqbal Khan, Shwetha Thukuntla, Kevin H. McKinney, Nicola I. Abate, Demidmaa Tuvdendorj · 2017 · British Journal of Pharmacology
91. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Yixing Li, Paul D. Rosenblit · 2018 · Current Cardiology Reports
92. Genetic control of the mouse HDL proteome defines HDL traits, function, and heterogeneity
    Nathalie Pamir, Calvin Pan, Deanna L. Plubell, Patrick M. Hutchins, Chongren Tang, Jake Wimberger, Angela D. Irwin, Thomas Q. de Aguiar Vallim, Jay W. Heinecke, Aldons Jake Lusis · 2019 · Journal of Lipid Research
93. A new phenotypic classification system for dyslipidemias based on the standard lipid panel
    Maureen L. Sampson, Rami A. Ballout, Daniel E. Soffer, Anna T Wolska, Sierra R. Wilson, Jeffrey W. Meeusen, Leslie J. Donato, Erica M. Fatica, James D. Otvos, Eliot A. Brinton et al. · 2021 · Lipids in Health and Disease
94. Dyslipidemia in Diabetes
    Ronald B Goldberg · 2022 · Endocrinology and Metabolism Clinics of North America
95. Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies
    R. Wilson King, Mario Enrico Canonico, Marc P. Bonaca, Connie Ng Hess · 2022 · Journal of the Society for Cardiovascular Angiography & Interventions
96. The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review
    Mostafa Abohelwa, Jonathan J. Kopel, Scott W. Shurmur, Mohammad Mostafa Ansari, Sanjay Awasthi, Sanjay Awasthi · 2023 · Journal of Vascular Diseases
97. HDL does not influence the polarization of human monocytes toward an alternative phenotype
    Sophie Colin, Mélanie Fanchon, Loïc Belloy, Andrea E. Bochem, Corinne Copin, Bruno Derudas, Erik S.G. Stroes, G. Kees Hovingh, Jan Albert Kuivenhoven, Geesje M. Dallinga‐Thie et al. · 2014 · International Journal of Cardiology
98. Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study
    Annelise Genoux, Jean‐Bernard Ruidavets, Jean Ferrières, Guillaume Combes, Laeticia Lichtenstein, Véronique Pons, Muriel Laffargue, Dorota Taraszkiewicz, Didier Carrié, Meyer Elbaz et al. · 2013 · Journal of Lipid Research
99. Atherosclerosis and Transit of HDL Through the Lymphatic Vasculature
    Catherine Martel, Gwendalyn J. Randolph · 2013 · Current Atherosclerosis Reports
100. Atherosclerotic cardiovascular disease risk and evidence-based management of cholesterol
     Satyajeet Roy · 2014 · North American Journal of Medical Sciences